ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
420 articles with ImmunoGen Inc.
-
ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress
10/20/2018
ImmunoGen Inc, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine
-
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results
10/18/2018
ImmunoGen, Inc. today announced that Company will host a conference call at 8:00a.m. on Friday, Nov 2, 2018.
-
ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO
10/8/2018
ImmunoGen, Inc. today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany.
-
Tesaro Highlights Benefits of Maintenance Therapy Zejula During Ovarian Cancer Awareness Month
9/25/2018
Ovarian cancer is the fifth leading cause of cancer-related deaths in the United States. It is estimated that this year there will be more than 22,000 women in the U.S. diagnosed with the disease and about 14,000 disease-related deaths. -
ImmunoGen Announces Webcasts of Presentations at Upcoming October 2018 Conferences
9/24/2018
ImmunoGen, Inc. today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—...
-
AIT Bioscience’s Terri Pascarelli Recognized as a 2018 PharmaVOICE 100 honoree
8/3/2018
AIT Bioscience, LLC Chief Executive Officer, Terri Pascarelli has been named among the 2018 PharmaVOICE 100 honorees.
-
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
7/27/2018
Mirvetuximab Soravtansine Granted Fast Track Designation by FDA
-
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer
6/18/2018
The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy.
-
ImmunoGen Announces Closing of Public Offering of Common Stock
6/11/2018
ImmunoGen Inc., Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $11.00 per share.
-
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
6/7/2018
ImmunoGen, Inc. today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of $11.00 per share.
-
ImmunoGen Announces Proposed Public Offering of 12,000,000 Shares of Common Stock
6/5/2018
ImmunoGen, Inc. announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common stock in an underwritten public offering.
-
ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference
5/30/2018
ImmunoGen, Inc. announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference.
-
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
-
ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
5/4/2018
ImmunoGen, Inc. reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.
-
ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference
5/2/2018
ImmunoGen, Inc. announced that the Company will present at the upcoming Deutsche Bank 43rd Annual Health Care Conference.
-
ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
4/26/2018
ImmunoGen, Inc. announced that the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer will continue as planned without modification.
-
ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer
4/25/2018
ImmunoGen, Inc. is a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer
-
ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.